



## Reversal of Issue of Shares

NEW YORK and SYDNEY, Australia, 14 June, 2023 - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), advises that the Company had issued 3,305,000 ordinary shares following shareholder approval at the Annual General Meeting held on 31 May 2023. The Company was originally intended to issue the shares on 30 June 2023 and due to administrative error those shares were issue on 9 June 2023.

The Company has instructed the Registry to reverse the issue of those shares and re-issue them on 30 June 2023. The number of shares held by directors post the re-issue of shares on 30 June 2023 remain the same hence the various Change of Director's Interest Notices will not be replaced.

The number of ordinary shares on issue following the reversal of 3,305,000 is 76,638,372. A separate announcement confirming the re-issue of shares will be released on 30 June 2023.

-End-

### About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit [www.beronigroup.com](http://www.beronigroup.com).

### Forward-Looking Statements Disclaimer

This press release contains forward-looking statements or forward-looking information, within the meaning of applicable United States and Australian securities laws with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as "anticipate", "will", "expect", "may", "continue", "could", "estimate", "forecast", "plan", "intend", "believe", "potential" and similar expressions.

Forward-looking information contained in this press release is based on Company management's opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward-looking statements involve significant risks, uncertainties and assumptions, and there can be no

assurance that such statements, or its underlying risks, uncertainties and assumptions will prove to be accurate. Factors that could cause actual results or events to differ materially include, without limitation, risks related to laws, rules and regulation applicable to the Company as well as the industry in which it operates (including in respect of taxes and other levies), economic or market conditions on both a national and global level, currency fluctuations, risks inherent to other entities at a similar stage of development and industry in which the Company currently is, competition from the Company's competitors, unsatisfactory development or marketing of the Company and/or its products or services, regulatory action or litigation (including product liability claims), and failure to enter into agreements or arrangements with other parties on fair or reasonable terms. Forward-looking information is made only as of the date on which it is provided and, except as may be required by applicable laws, the Company disclaims any intent or obligation to update such forward-looking information whether as a result of new information, future events or otherwise.

For more information, please contact us at:

Tel: +61 2 9159 1827

Email: [enquiry@beronigroup.com](mailto:enquiry@beronigroup.com)

Website: [www.beronigroup.com](http://www.beronigroup.com)